Interleukin-2 therapy of human cancer: potential benefits versus toxicity

Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ.

Cancer research·1992

The T-cell receptor V beta gene usage in tumor-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma.

Cancer research·1992

Nongranular proteolytic enzymes of rat IL-2-activated natural killer cells. I. Subcellular localization and functional role.

Journal of immunology (Baltimore, Md. : 1950)·1992

Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells.

International journal of cancer·1992

Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.

Journal of immunology (Baltimore, Md. : 1950)·1992

Tissue distribution of adoptively transferred adherent LAK cells: role of the route of administration.

Natural immunity·1992

Financial Payments From Drug Manufacturers to Oncologists and Use of Guideline-Preferred Cancer Treatments.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Recent Population-Level Trends in Utilization of Outpatient Medical Oncology Services.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Circulating Tumor DNA Profiling Defines Risk Classification in Patients With Ewing Sarcoma: A Report From the Children's Oncology Group and the LEOPARD Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR-Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Invited submission to Reproduction and Fertility for "Evolving Perspectives in Management of Menopause Transition" Series.

Reproduction & fertility·2026

Collagen-Binding IL-15 Immunocytokine Armed Oncolytic Adenovirus Establishes a Self-Reinforcing Immunostimulatory Milieu to Potentiate Antitumor Immunity.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Breaking the Lipid Bottleneck: A Mitophagy-Driven Nanoregulator Amplifies Ferroptosis for Colorectal Cancer Immunotherapy.

Small (Weinheim an der Bergstrasse, Germany)·2026

Body Composition and Physical Activity are Associated With Prediabetes in Childhood, Adolescent, and Young Adult Cancer and Hematopoietic Cell Transplantation Survivors.

Pediatric blood & cancer·2026

Real-World Determinants of Treatment Selection in Frontline Chronic Lymphocytic Leukemia: The FIRST-CLL Study.

Hematological oncology·2026

Metastasis-directed local therapy and strategic de-escalation of systemic therapy for oligometastatic esophageal squamous cell carcinoma.

Japanese journal of clinical oncology·2026

Related Experiment Videos

Interleukin-2 therapy of human cancer: potential benefits versus toxicity

Related Concept Videos

Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ.

The T-cell receptor V beta gene usage in tumor-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma.

Nongranular proteolytic enzymes of rat IL-2-activated natural killer cells. I. Subcellular localization and functional role.

Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells.

Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.

Tissue distribution of adoptively transferred adherent LAK cells: role of the route of administration.

Financial Payments From Drug Manufacturers to Oncologists and Use of Guideline-Preferred Cancer Treatments.

Recent Population-Level Trends in Utilization of Outpatient Medical Oncology Services.

Circulating Tumor DNA Profiling Defines Risk Classification in Patients With Ewing Sarcoma: A Report From the Children's Oncology Group and the LEOPARD Study.

P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR-Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape.

Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial.

Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making.

Invited submission to Reproduction and Fertility for "Evolving Perspectives in Management of Menopause Transition" Series.

Collagen-Binding IL-15 Immunocytokine Armed Oncolytic Adenovirus Establishes a Self-Reinforcing Immunostimulatory Milieu to Potentiate Antitumor Immunity.

Breaking the Lipid Bottleneck: A Mitophagy-Driven Nanoregulator Amplifies Ferroptosis for Colorectal Cancer Immunotherapy.

Body Composition and Physical Activity are Associated With Prediabetes in Childhood, Adolescent, and Young Adult Cancer and Hematopoietic Cell Transplantation Survivors.

Real-World Determinants of Treatment Selection in Frontline Chronic Lymphocytic Leukemia: The FIRST-CLL Study.

Metastasis-directed local therapy and strategic de-escalation of systemic therapy for oligometastatic esophageal squamous cell carcinoma.

Related Experiment Videos

Interleukin-2 therapy of human cancer: potential benefits versus toxicity

Related Concept Videos

Related Articles